Bioactive glass
PreclinicalSmall molecule
Bioactive glass is one of 30 small molecule programs targeting Surgery. It is currently in Preclinical.
3
Indications
5
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Surgery
#DrugCompanyPhaseTrials
1Journavx
Vertex PharmaceuticalsApproved
Alfenta
Jazz PharmaceuticalsApproved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Levophed
GGeneral Hospital of Ningxia Medical University
Approved
Nubain
AAultman Health Foundation
Approved
Desferal
Jazz PharmaceuticalsPhase 3
Cardene
Sun Pharmaceutical Industries, Inc.Phase 2
Tukysa
PfizerPhase 2
Senna
MMedtronic - MITG
Phase 3
Inlyta
PPrism Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dentin Hypersensitivity1 trial
Effect of Gluma and Bioactive Glass Desensitizers in Treatment of Dentin Hypersensitivity in Cervical Non-Carious Lesions
Completed·—·N/A·NCT07063433·40 enrolled
Surgery1 trial
Socket Seal Surgery
Completed·—·N/A·NCT06764732·45 enrolled
Dentinal Hypersensitivity1 trial
Unspecified1 trial
Bioactive Glass and Platelet Rich Fibrin in Intrabony Defects
Completed·—·Phase 3·NCT02982681·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bioactive glass. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- KKing Abdulaziz University